IL6 and plasma cell myeloma: IL-6, a growth and survival factor for myeloma cells, is among those cytokines that activate JAK2 and ultimately augment its downstream signaling effects [8]; and, therefore, JAK inhibitors represent potential therapies for treating MM patients.